ABSTRACT
We describe the case of a 74-year-old woman with previous history of gastric signet cell carcinoma who develops bladder metastasis as first sign of recurrence 6 years later. Bladder metastasis due to signet cell carcinoma is extremely rare with only 19 cases reported. Treatment includes radical cystectomy or chemotherapy.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carcinoma, Signet Ring Cell , Cystectomy/methods , Stomach Neoplasms , Urinary Bladder Neoplasms , Aged , Carcinoma, Signet Ring Cell/pathology , Carcinoma, Signet Ring Cell/secondary , Chemotherapy, Adjuvant/methods , Female , Fluorouracil/administration & dosage , Gastrectomy/adverse effects , Gastrectomy/methods , Humans , Immunohistochemistry , Leucovorin/administration & dosage , Neoplasm Staging , Neoplasms, Second Primary/pathology , Organoplatinum Compounds/administration & dosage , Stomach Neoplasms/pathology , Stomach Neoplasms/therapy , Tomography, X-Ray Computed/methods , Treatment Outcome , Urinary Bladder Neoplasms/pathology , Urinary Bladder Neoplasms/secondaryABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Colorectal Neoplasms/pathology , Bile Duct Neoplasms/surgery , Neoplasm Metastasis/pathology , Bile Duct Neoplasms/secondary , Neoplasm Recurrence, Local/surgerySubject(s)
Adenocarcinoma/secondary , Adenocarcinoma/surgery , Bile Ducts, Intrahepatic/surgery , Colorectal Neoplasms/pathology , Hepatectomy/methods , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Adenocarcinoma/prevention & control , Bile Duct Neoplasms/prevention & control , Disease Progression , Drainage , Female , Humans , Middle AgedABSTRACT
No disponible
Subject(s)
Aged , Humans , Male , Catheter Ablation/methods , Liver Neoplasms/surgery , Neoplasm Metastasis , Necrosis/etiology , Postoperative Complications , Colonic Neoplasms/pathologyABSTRACT
No disponible
Subject(s)
Humans , Male , Aged , Hepatectomy/methods , Embolization, Therapeutic/methods , Colonic Neoplasms/surgery , Liver Neoplasms/surgery , Ligation , Liver Neoplasms/secondary , Neoplasm MetastasisSubject(s)
Adenocarcinoma/surgery , Fiducial Markers , Hepatectomy/methods , Liver Neoplasms/surgery , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Adenocarcinoma/secondary , Chemotherapy, Adjuvant , Colorectal Neoplasms/pathology , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/pathology , Liver Neoplasms/secondary , Male , Middle Aged , Neoadjuvant TherapyABSTRACT
BACKGROUND AND OBJECTIVE: Multiple myeloma (MM) is a plasm-cell neoplasm characterized by a monoclonal protein in the serum or urine. Thalidomide is effective as second line treatment. PATIENTS AND METHOD: We performed a retrospective study of 36 consecutive patients with refractory MM treated with thalidomide and dexamethasone as second line therapy, with the objective of analyzing the rate of response (primary end point), progression-free survival (PFS) and toxicity profiles (second end points). RESULTS: In our study the overall response rate was 55.6%, with a median of PFS of 12.6 months (95% confidence interval: 4-21 months). PFS at 6, 12 and 18 months was 61.11%, 50% and 22.22% respectively. 30.6% of the patients had neuropathy, 11.11% had rash and 5.55% had deep vein thrombosis. CONCLUSIONS: The combination of thalidomide and dexamethasone is an effective and safe second line treatment for refractory MM, with a manageable toxicity.
Subject(s)
Dexamethasone/therapeutic use , Multiple Myeloma/drug therapy , Thalidomide/therapeutic use , Adult , Aged , Aged, 80 and over , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Retrospective StudiesABSTRACT
Fundamento y objetivo: El mieloma múltiple (MM) es una neoplasia de células plasmáticas que se caracteriza por la presencia de una proteína monoclonal en suero u orina. La talidomida es un fármaco eficaz en el tratamiento de segunda línea de esta enfermedad. Pacientes y método: Hemos realizado un estudio retrospectivo de una serie de 36 casos consecutivos con MM pertinaz a los que hemos tratado con talidomida y dexametasona en segunda línea, con el objetivo de analizar la tasa de respuesta (objetivo primario), la supervivencia libre de progresión (SLP) y toxicidad (objetivos secundarios). Resultados: En nuestro estudio hemos encontrado una tasa de respuesta total del 55,6%, una mediana de SLP de 12,6 meses (intervalo de confianza del 95%, 4-21 meses). La SLP a los 6, 12 y 18 meses fue del 61,11, el 50 y el 22,22% respectivamente. El 30,6% de los pacientes presentaron neuropatía; el 11,11%, erupción cutánea y el 5,55%, enfermedad tromboembólica. Conclusiones: La combinación de talidomida y dexametasona es un tratamiento efectivo y seguro en segunda línea para pacientes con MM resistente al tratamiento, con una toxicidad manejable
Background and objective: Multiple myeloma (MM) is a plasm-cell neoplasm characterized by a monoclonal protein in the serum or urine. Thalidomide is effective as second line treatment. Patients and method: We performed a retrospective study of 36 consecutive patients with refractory MM treated with thalidomide and dexamethasone as second line therapy, with the objective of analyzing the rate of response (primary end point), progression-free survival (PFS) and toxicity profiles (second end points). Results: In our study the overall response rate was 55.6%, with a median of PFS of 12.6 months (95% confidence interval: 4-21 months). PFS at 6, 12 and 18 months was 61.11%, 50% and 22.22% respectively. 30.6% of the patients had neuropathy, 11.11% had rash and 5.55% had deep vein thrombosis. Conclusions: The combination of thalidomide and dexamethasone is an effective and safe second line treatment for refractory MM, with a manageable toxicity
